Disease · MONDO_0005184

pancreatic ductal adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pancreatic ductal adenocarcinoma. Diseases, record MONDO_0005184. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005184

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pancreatic ductal adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005184; Open Targets
Other names: PDAC, ductal adenocarcinoma of pancreas, ductal adenocarcinoma of the pancreas, pancreas ductal adenocarcinoma, pancreas tubular adenocarcinoma, pancreatic duct adenocarcinoma, pancreatic ductal carcinoma, pancreatic tubular adenocarcinoma; Open Targets
Disease Ontology: DOID:3498; Disease Ontology
Disease Ontology: DOID:3587; Disease Ontology
MeSH: D021441; MeSH
NCI Thesaurus: C9120; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 27 of its 240 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs240

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	136	136	134	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	122	122	76	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	65	65	46	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	63	63	47	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	51	51	34	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Phase 3	ClinicalTrials.gov	28	28	17	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 3	ClinicalTrials.gov	28	28	21	Drugs and targets
IRINOTECAN HYDROCHLORIDE	CHEMBL3989514	Small molecule	Phase 3	ClinicalTrials.gov	24	24	11	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	20	20	19	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	19	19	19	Drugs and targets

1 to 10 of 240

See all 240 drugs

Targets265

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	14	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
CD274	Programmed cell death 1 ligand 1	6	Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 3	https://conductscience.org/library/genes/29126	Drugs and targets
EGFR	Epidermal growth factor receptor	5	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	5	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 2	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	5	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 2	https://conductscience.org/library/genes/5605	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	4	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 3	https://conductscience.org/library/genes/1493	Drugs and targets
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
PARP1	PARP 1, 2 and 3	4	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/142	Drugs and targets
PARP2	PARP 1, 2 and 3	4	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor	Phase 2/3	https://conductscience.org/library/genes/10038	Drugs and targets
TOP1	DNA topoisomerase 1	4	DNA topoisomerase I inhibitor	Phase 3	https://conductscience.org/library/genes/7150	Drugs and targets

1 to 10 of 265

See all 265 targets

Trials306

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 11 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02993731	A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma	Phase 3	1,134	2021-06-10	Carcinoma, Pancreatic Ductal	GEMCITABINE, NAPABUCASIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02715804	A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	Phase 3	492	2020-07-14	Pancreatic Ductal Carcinoma	GEMCITABINE, PACLITAXEL, PEGVORHYALURONIDASE ALFA	Its record names the disease	ClinicalTrials.gov
NCT01494506	Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer	Phase 3	417	2016-02-12	Metastatic Pancreatic Cancer	FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM	Its record names the disease	ClinicalTrials.gov
NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	Phase 1/2	341	2025-11-21	Pancreatic Adenocarcinoma	ATEZOLIZUMAB, BEVACIZUMAB, COBIMETINIB, ETRUMADENANT, FLUOROURACIL, GEMCITABINE, LEUCOVORIN, MOTIXAFORTIDE, OXALIPLATIN, PACLITAXEL, PEGVORHYALURONIDASE ALFA, SELICRELUMAB, SIMLUKAFUSP ALFA, TIRAGOLUMAB, TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01782690	An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer		338	2018-07-23	Pancreatic Cancer	ERLOTINIB, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT01839487	PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer	Phase 2	279	2020-07-20	Metastatic Pancreatic Cancer	GEMCITABINE, PACLITAXEL, PEGVORHYALURONIDASE ALFA	Its record names the disease	ClinicalTrials.gov
NCT03611556	MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.	Phase 1/2	213	2023-10-03	Carcinoma, Metastatic Pancreatic Adenocarcinoma	DURVALUMAB, OLECLUMAB	Its record names the disease	ClinicalTrials.gov
NCT03943667	Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	211	2026-01-15	Metastatic Pancreatic Adenocarcinoma	GEMCITABINE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02289898	Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	207	2018-08-08	Pancreatic Cancer	DEMCIZUMAB, GEMCITABINE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT04390763	Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Phase 2	164	2025-05-28	Metastatic Pancreatic Ductal Adenocarcinoma	GEMCITABINE, PACLITAXEL, SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 306

See all 306 trials

Comparisons in its trials52

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): Number of Patients With Adverse Events	560 of 561	543 of 547	1,108	NCT02993731	Trial comparisons
Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): deaths from any cause	419 of 561	400 of 547	1,108	NCT02993731	Trial comparisons
Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): serious adverse events	330 of 561	273 of 547	1,108	NCT02993731	Trial comparisons
PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine vs AG: Placebo + Nab-Paclitaxel + Gemcitabine: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)	8 of 325	4 of 156	481	NCT02715804	Trial comparisons
PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine vs AG: Placebo + Nab-Paclitaxel + Gemcitabine: Number of Participants With Treatment-Emergent Adverse Events (AEs)	325 of 325	156 of 156	481	NCT02715804	Trial comparisons
PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine vs AG: Placebo + Nab-Paclitaxel + Gemcitabine: deaths from any cause	222 of 325	106 of 156	481	NCT02715804	Trial comparisons
PAG: PEGPH20 + Nab-Paclitaxel + Gemcitabine vs AG: Placebo + Nab-Paclitaxel + Gemcitabine: serious adverse events	187 of 325	80 of 156	481	NCT02715804	Trial comparisons
PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine vs AG: Nab-paclitaxel + Gemcitabine: deaths from any cause	131 of 166	87 of 113	279	NCT01839487	Trial comparisons
PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine vs AG: Nab-paclitaxel + Gemcitabine: serious adverse events	101 of 160	58 of 100	260	NCT01839487	Trial comparisons
GEMPAX vs Control: deaths from any cause	131 of 140	68 of 71	211	NCT03943667	Trial comparisons

1 to 10 of 52

See all 52 comparisons in its trials

Papers from its trials138

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38237621	RESULT	1	PubMed
31976786	RESULT	1	PubMed
31157963	RESULT	1	PubMed
29808006	RESULT	1	PubMed
29232172	RESULT	1	PubMed
29119276	RESULT	1	PubMed
28348497	RESULT	1	PubMed
23547081	RESULT	1	PubMed
21994333	RESULT	1	PubMed
42971953	DERIVED	1	PubMed

1 to 10 of 138

See all 138 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005184

GET https://conductscience.org/api/diseases/v1/MONDO_0005184/drugs?page=2

API reference For AI assistants